U.S. Markets closed

Why AbbVie Is Focused on Expanding Risankizumab’s Label for Multiple Immunology Indications

Margaret Patrick
Why AbbVie Is Focused on Expanding Risankizumab’s Label for Multiple Immunology Indications

AbbVie (ABBV) is focused on expanding Risankizumab’s label for multiple indications such as psoriatic arthritis, ulcerative colitis, and Crohn’s disease. The company expects to witness a significant rise in demand for Crohn’s disease and ulcerative colitis patients, mainly driven by increasing diagnosis rates and the greater prevalence of patients already treated with biologics.